Claim Missing Document
Check
Articles

Found 39 Documents
Search

Correlation between Serum Interleukin-6 Level and Modified Rodnan Skin Score in Systemic Sclerosis Patients Dania Artriana Riswandi; Sumartini Dewi; Andri Reza Rahmadi
International Journal of Integrated Health Sciences Vol 9, No 2 (2021)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v9n2.2478

Abstract

Objective: To determine the correlation between serum levels of IL-6 and MRSS in systemic sclerosis patients.Methods: This was a crossectional observational study on patients with SSc visiting the Rheumatology Clinic of Dr. Hasan Sadikin General Hospital Bandung, Indonesia from January 2019 to December 2020. Registered SSc patients, with validated MMRS by a rheumatologist, and available biological materials for IL-6 measurement were included. Patients with other autoimmune diseases, acute infection, diabetes mellitus, and obesity were excluded from this studyResults: Of the 51 SSc patients, 42 patients met the inclusion criteria. Women comprised the majority of these patients (95.2%), while patients’ mean age was 43±12 years. The mean duration of disease was 20 months, with diffuse SSc (78.6%) as the most frequent type. Bivariate analysis showed that IL-6 was positively correlated with MRSS (100-scale) with r=0.397 and p=0.005.Conclusion: There is a medium positive correlation between MRSS and interleukin-6 serum among systemic sclerosis patients visiting Dr. Hasan Sadikin General Hospital Bandung, Indonesia. 
Hook effect and serum KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Emmy Hermiyanti Pranggono; Valentine Natasya Moenardi; Alvy Syukrie; Sumartini Dewi
International Journal of Integrated Health Sciences Vol 9, No 2 (2021)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v9n2.2488

Abstract

Objective To determine whether serum KL-6 can be used as an alternative diagnostic tool for Systemic Sclerosis-associated ILD (SSc-ILD).Method This was a cross-sectional study with compatibility analysis of SSc patients visiting the rheumatology clinic of Dr. Hasan Sadikin General Hospital, Bandung, Indonesia in 2019-2020. Inclusion criteria were aged 18-60 years, diagnosed with SSc, restrictive spirometry results followed by HRCT thorax, having stored biological materials (<2 years) for serum KL-6 examination, and body mass index of <23 kg/m2. Patients with pneumonia, tuberculosis, history of tuberculosis, malignancy, and cardiac decompensation were excluded. Serum KL-6 level of >397.5 unit/mL was declared as ILD. The compatibility analysis was performed using the Cohen’s Kappa test.Results: Thirty-eight subjects, mostly women (94.7%), with mean age of 39 years participated in this study. Most of the subjects suffered from diffuse systemic sclerosis subtypes (57.9%). Subjects had received cyclophosphamide (10.5%), MMF (2.6%), and other medications. Almost all subjects (97.4%) demonstrated ILD features on HRCT thorax. The median serum KL-6 level was 53.22 Units/mL, which was much lower than the findings in other studies, but the hook effect could not be proven. The Kappa coefficient was found to be 0.003 with a p-value of 0.811.Conclusion There is no compatibility between serum KL-6 level and ILD features based on HRCT thorax in SSc-ILD. The presence of hook effect needs more attention.
Effectivity and safety of mahkota dewa fruit extract compared to meloxicam (phaleria macrocarpa fructus) on osteoarthritis Andri Reza Rahmadi; Sumartini Dewi; A Nawawi; I K Adnyana; Rachmat Gunadi Wachjudi
Indonesian Journal of Rheumatology Vol. 8 No. 1 (2016): Indonesian Journal of Rheumatology
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (293.214 KB) | DOI: 10.37275/ijr.v8i1.9

Abstract

Background: Osteoarthritis (OA) is the most common musculoskeletal disease. World Health Organization (WHO) estimates that 10% of the aged over 60 year population have this disease. The aim of OA treatment is to reduce pain, which is the most OA patients chiefcomplaint. People in Indonesia are very interested in use of herbal therapies from original traditional plant to treat pain now, one of the traditional plants that are known havea benefit is Phaleria macrocarpa or Mahkota Dewa fruit. Phaleria macrocarpa has been shown to decrease the degree of inflammation of OA animal model experiments. In order to know what is the effect of this fruit extract to reduce degrees of pain and change the levels of IL-1, IL-6, TNF-α in the blood as the marker of inflammation of patients with knee OA, and what is the effects to liver, kidney and haematology in the Indonesian population hasnot been investigated Methods: The research method is an experimental study and the research design is PROBE (Prospective Randomized Open End Blinded Evaluation), to evaluate the efficacy of the extract Mahkota Dewa fruit (Phaleria macrocarpa fructus) 330 mg (Super Mahkota POMTR 053 345 491) compared to meloxicam 7.5 mg in patients with knee osteoarthritis. The study population was outpatients with knee OA at Rheumatology Clinic Dr Hasan Sadikin Hospital Bandung. Patients are given Phaleria macrocarpa 330 mg or meloxicam 7.5 mg once a day for 14 days. Observations were made to evaluate the degree of pain as measured by VAS and Lequesne index at day 0, day 14 and measured again at day 28,after they are not taking the extract anymore.Results: Phaleria macrocarpa 330 mg is equal to meloxicam 7.5 mg in reducing the degree of pain as measured by VAS (p=0.78) and the Lequesne index (p=0.51). Our finding, t here is no effect of decreasing the proinflammatory cytokine IL-1 (p=0.72), IL-6(p=0.53) and TNF-α (p=0.07) in the blood of both groups. Safety analysis shown that this extract is safe for consumption.Conclusions: Phaleria macrocarpa 330 mg equal to meloxicam 7.5 mg in reducing the degree of pain however there is no effect on reducing proinflammatory cytokines in the blood of OA patients who had received therapy for 14 days in both groups. There is no adverse effects found on hematological, liver function and kidney function after consumption this plant’s fruit extract.Keywords: osteoarthritis, mahkota dewa, phaleria macrocarpa
Calcinosis and myocarditis in systemic lupus erythematosus patient Sumartini Dewi; Rachmat Gunadi Wachjudi
Indonesian Journal of Rheumatology Vol. 1 No. 2 (2009): Indonesian Journal of Rheumatology
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (205.657 KB) | DOI: 10.37275/ijr.v2i1.28

Abstract

Systemic lupus erythematosus (SLE) patients have multi-organ involvement related to their chronic inflammatory, autoimmune disease. Calcinosis can be clinical manifestations of SLE. Tissue calcinosis is reported in approximately 17% patients and myocarditis in 20-55% patients. Thus, both manifestations are not unusual in SLE. Tachypnea, tachycardia, pericardial effusion, and wheezing are often present and can be misleading in SLE patient.1,2 Calcinosis is less common in SLE, sometimesit is found as an incidental radiological finding. Calcification in SLE maybe periarticular, within joints or muscles, or in the subcutis (calcinosis universalis).1 Calcinosis is classified into four subsets: dystrophic, metastatic, idiopathic, or calciphylaxis/iatrogenic. When calcinosis cutis is isolated to a small area in extremities and joints, it is called calcinosis circumscripta; whereas its diffuse form, refers to calcinosis universalis, affects subcutaneous and fibrous structures of muscles and tendons. The pathophysiology of this condition is unknown and no effective therapy is currently available.3,4,5 Systemic lupus erythematosus can involve the myocardium, pericardium, cardiac valves,and coronary arteries. Myocarditis in SLE is not likely to produce major regional wall motion abnormalities but may contribute to global left ventricular dysfunction.7,8We report a young woman with SLE who developed calcinosis and myocarditis.
Arthritis in leprosy without specific skin lesion Sumartini Dewi; Bambang Setiyohadi
Indonesian Journal of Rheumatology Vol. 2 No. 1 (2010): Indonesian Journal of Rheumatology
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (145.357 KB) | DOI: 10.37275/ijr.v2i2.34

Abstract

Leprosy patients could display a great variability of signs and symptoms. An overabundance of rheumatic manifestations, occuring alone or in varying combinations, are associated with leprosy, particularly with lepra reactions A study involving seventy cases of leprosy found that rheumatic manifestations were seen in 61.42% of cases: arthritis in 54.28% and soft tissue rheumatism in 17.14%. Enthesitis was seen in 2.84% of cases. Rheumatic manifestations may be the primary complaint, thus delaying accurate diagnosis. Musculoskeletal involvement in leprosy is the third most frequent manifestation after dermatological and neurological involvements. It can occur at anytime during the infection. Articular inflammation in leprosy, which closely mimics other rheumatic disorders, usually occurs in reactive states, particularly erythema nodosum leprosum (ENL).1 About 1–5% of leprosy patients are reported of developing arthritis (synovial inflammation) at some stage of the disease but this rate increases to over 50% during lepra reactions.2 Here we report a case of arthritis in leprosywithout any typical skin lesion thus causing a delay in diagnosis.
Multiple autoimmune syndrome (Graves’ disease, systemic lupus erythematosus, and systemic sclerosis) in a young woman in Jakarta Sumartini Dewi; Bambang Setiyohadi; M I Mokoagow
Indonesian Journal of Rheumatology Vol. 2 No. 1 (2010): Indonesian Journal of Rheumatology
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (146.308 KB) | DOI: 10.37275/ijr.v2i2.37

Abstract

Multiple autoimmune syndrome (MAS) is a condition in which patients have at least threedistinct autoimmune conditions. The definition of MAS is based on 91 reported cases of such associations in the literature. A review of the literature and cluster analysis of MAS disclosed systemic lupus erythematosus (SLE), Sjögren’s syndrome, and autoimmune thyroid disease (AITD) as the “chaperones” of autoimmune diseases. This entity was described by Humbert and Dupond in 1988 as a syndrome consisting of the presenceof three or more autoimmune diseases in a single patient. While describing the syndrome, their observations led them to a rough classification of clusters based on the co-occurrence of autoimmune disease, which they identified as types one through three.1 In MAS-1, the authors grouped myasthenia gravis, thymoma, dermatopolymyositis, and autoimmune myocarditis together. In MAS-2, they grouped Sjögren’s syndrome, rheumatoid arthritis,primary biliary cirrhosis, systemic sclerosis (SSc), and AITD. MAS-3 consists of AITD, myasthenia gravis and/or thymoma, Sjögren’s syndrome, pernicious anemia, idiopathic thrombocytopenic purpura, Addison’s disese, type 1 diabetes, vitiligo, autoimmune hemolytic anemia, and SLE.1,2,3 The importance of this concept is the probability thathaving three autoimmune diseases simultaneously in one patient goes beyond epidemiological inferences or statistical chance. Disorders of autoimmune pathogenesis occur with increased frequency in patients with a history of another autoimmune disease. The tendency to develop another disease occurs in about 25% of these patients.3,4 We report a case in which the presence of Graves’ disease/AITD, SLE, vasculitis, and SSc with pulmonary hypertension and Raynaud’s phenomenon in one patient
Correlation between Serum Krebs von den Lungen-6 Levels with Forced Vital Capacity and Modified Rodnan Skin Score of Patients with Restrictive Lung Disease in Diffuse-Type Systemic Sclerosis Herlina Yani; Sumartini Dewi; Andri Reza Rahmadi
Indonesian Journal of Rheumatology Vol. 11 No. 2 (2019): Indonesian Journal of Rheumatology
Publisher : Indonesian Rheumatology Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ijr.v11i2.133

Abstract

Background Pulmonary fibrosis / intersitial lung disease (ILD) in systemic sclerosis (SSc) is a complicated restrictive pulmonary disease and the leading cause of disease-related mortality. Progressive skin fibrosis in diffuse-type SSc (dSSc) is associated with decreased forced vital capacity (FVC). Modified Rodnan Skin Score (mRSS) examination is used as a parameter to assess skin fibrosis, while high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) are used to assess pulmonary fibrosis. The HRCT test remains as the gold standard in diagnosing ILD. However, it costs a lot and is not available in all healthcare facilities. Krebs Von den Lungen-6 (KL-6) is a biomarker to evaluate pulmonary fibrosis. The aim of this study was to analyze the correlation of serum KL-6 levels with FVC and mRSS value of patients with restrictive lung disease in dSSc. Method This was a cross-sectional study that used primary data from dSSc patients who visited rheumatology outpatient clinic in Hasan Sadikin Hospital Bandung, Indonesia, during the period of June-July 2019. History taking, physical examination, mRSS, spirometry, and serum KL-6 levels were performed. Data were analyzed using the Rank Spearman correlation test. Result There were 27 subjects with the mean age of 42 ± 12 years. Based on FVC (%) restrictive lung disease criteria, the majority of subjects (74.1%) had severe restrictive lung disease and the rest of all subjects (25.9%) were non severe restrictive lung disease. Serum KL-6 levels ranged from 0.545 to 8.138 ng/ml. The results showed that there was no correlation between serum KL-6 levels and FVC values (r = -0.118, p = 0.279) and mRSS (r = 0.101, p = 0.312 ). Conclusion There is no correlation between serum KL-6 levels with FVC and mRSS value of patient with restritive lung disease in diffuse type systemic sclerosis. Keywords : diffuse type systemic sclerosis, Forced Vital Capacity, KL-6, mRSS, restrictive lung disease.
Correlation between serum KL-6 level and severity of SARD-related ILD Emmy Pranggono; Alvy Syukrie; Valentine Natasya Moenadri; Sumartini Dewi
International Journal of Integrated Health Sciences Vol 10, No 1 (2022)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v10n1.2652

Abstract

Objective: To understand the correlation between serum KL-6 level and severity of SARD-related ILD in Indonesia.Method: This was a cross-sectional study to evaluate the correlation between serum KL-6 level and Interstitial Lung Disease (ILD) severity based on Chest High-Resolution Computed Tomography (Chest HCRT) among patients with Systemic Autoimmune Rheumatic Disorders (SARD) who visited the Rheumatology Clinic of Dr. Hasan Sadikin General Hospital during the period of January 2019 to February 2020. Secondary data were retrieved from a study on the Effects of Ciplukan Herbs on Organ Fibrosis. KL-6 serum concentration was measured from stored biological material and the correlation between the serum KL-6 level and ILD severity was analyzed by Rank Spearman's test.Results: Thirty-four patients participated in this study with a median age of 37 years-old. Most of the participants were female (94.1%), Sundanese (64.7%), and had systemic sclerosis as an underlying disease (48.5). The median serum KL-6 level was 57.1 U/ml (21.6-444.1). Most participants belonged to severe ILD group (58.8%) with a mean serum KL-6 level of 65.1±48.9 U/ml. The highest mean serum KL-6 level (111.6±121.8) was observed in the moderate ILD group comprising of 32.4% of the participants. The remaining 11.8% participants belonged to mild ILD group with a mean serum KL-6 level of 61.1±24.9 U/ml. Serum KL-6 level was demonstrated to have a weak correlation with ILD severity (r=-0.229, p=0.193).Conclusion. There is an insignificant weak correlation between serum KL-6 level and ILD severity based on chest HRCT in SARD patients.
CORRELATION BETWEEN COGNITIVE FUNCTION AND SERUM LEVELS OF TUMOR NECROSIS ALPHA (TNF-α) IN SCHIZOPHRENIA Eldi Sauma; Antania Hanjani Irianti; Tuti Kurnianingsih; Shelly Iskandar; Sumartini Dewi; Veranita Pandia
Majalah Kedokteran Andalas Vol 46, No 8 (2024): Online Januari 2024
Publisher : Faculty of Medicine, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/mka.v46.i8.p1261-1270.2024

Abstract

Introduction: Impaired cognitive function causes significant impairment in schizophrenic patients. Studies result found that inflammatory processes in the brain play an important role in cognitive decline in schizophrenia. One of the inflammatory markers associated with cognitive function in schizophrenia is serum Tumor Necrosis Factor Alpha (TNF-α) levels. TNF-α levels can be influenced by genetic and racial factors.   Objective: This study aims to analyze the correlation between cognitive function and TNF-α serum levels in schizophrenic patients in Indonesia. Methods: This study is an analytical study using a cross-sectional design in 34 schizophrenic patients who were hospitalized in the Mental Hospital of West Java Province. Patients with risk of inflammation and cognitive impairment are excluded. Cognitive function was assessed using the Rey Auditory Verbal Learning Test (RAVLT), Digit Span and Trail Making Test. TNF-α serum levels were measured using the Sandwitch-ELISA (Enzyme-linked Immunosorbent Assay) method. Results: Study participants showed a cognitive deficit in all examination instruments. The TNF-α serum levels of the participants increased (mean: 8.93 ± 3.43). TNF-α serum levels was not significantly correlated with cognitive function. Conclusion: There is no significant correlation exist between cognitive function and TNF-α serum levels in schizophrenia.Keywords: Schizophrenia, cognitive function, TNF-α
Personal Data Theft in the Era of Information Technology Progress: Impact and Overcoming Strategies in Indonesia Dewi, Sumartini; Samara, Muchlas Rastra; Sri D, Pratiwi Ayu
UNTAG Law Review Vol 8, No 1 (2024): UNTAG LAW REVIEW
Publisher : Faculty of Law Universitas 17 Agustus 1945 Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56444/ulrev.v8i1.4992

Abstract

This article examines the problem of information security crimes in the conditions of technological progress with the globalization of international life, including relations between countries, taking into account the high level of development of technological and information resources. The importance of ensuring information security as an object of legal protection protected by written international and national law. This research method is normative with a statutory, historical and philosophical approach. efforts to improve international and national legal policies to modernize the national legal system for the prevention and eradication of cybercrime. An effective legal regulatory mechanism for objects to be legally protected is essential to ensure information security. Special attention is focused on solving the problem of detection, disclosure and accurate legal evaluation of crimes and violations committed in cyberspace. Administrative instruments, institutions, international cooperation, community participation, dispute resolution and procedural law, prohibitions on the use of personal data and criminal law asLast Remedyto overcome personal data leaks, protect personal data in the process of processing Personal Data in order to guarantee people's constitutional rights.
Co-Authors A Nawawi Achmad Jaelani Ade Zuhrotun Adnyana, I K Alfarish, M Arzan Alvy Syukrie Alvy Syukrie Andri Reza Rahmadi Anna Tjandrawati Antania Hanjani Irianti Bambang Setiyohadi Bambang Setiyohadi Bambang Setiyohadi Binti Ahamad Naina, Hamizah Sabrina Budiman, Annisa Meivira Dania Artriana Riswandi Destiani, Nadia Ayu Dolvy Girawan Dwi Nurahman Dwinanda Linchia Levi Heningdyah Nikolas Kusumawardhani Eldi Sauma Emmy Hermiyanti Pranggono Emmy Pranggono Enny Rohmawaty Guntur Darmawan Hamizah Sabrina Binti Ahamad Naina Herlina Yani Herry Pasrani Mendrofa Hesti Lina Wiraswati I Ketut Adnyana Iceu Dimas Kulsum Ine Kuswardinah Irianti, Antania Hanjani Juhari Hasan Kurnianingsih, Tuti Kuswardinah, Ine Laniyati Hamijoyo, Laniyati Levi Heningdyah Nikolas, Dwinanda Linchia Logito, Verina M I Mokoagow Marina A. Moeliono Marina A. Moeliono, Marina A. Maslim, Y Mokoagow, M I Muchlas Rastra Samara Muksin Muhammad Begawan Bestari Nadia Ayu Destiani Nawawi, A Nenny Agustanti Nofan Pratama Maulana Oehadian, A Pang Sze Lyn Prananta, Marietta Shanti Rachmat Gunadi Wachjudi Rini Hendriani Rosdianto, Aziiz Mardanarian Salim, Susanto Samuji Saragih, Winda A. M. Saragih, Winda Agnestia Maranna Savira Ekawardhani Shelly Iskandar Siti Nur Fatimah Siti Nur Fatimah Sri D, Pratiwi Ayu Sri Setiawati Stelvia W. Noya SUNARTO Sze Lyn, Pang Tuti Kurnianingsih Tuti Kurnianingsih Usman, Hermin A. Usman, Stefanie Yuliana Valentine Natasya Moenadri Valentine Natasya Moenardi Veranita Pandia Vincent Vincent, Vincent Waliyyuddin Robbani Widayanti Widayanti Wijaya, Muhammad Palar Wina Widiati Yoga Windhu Wardhana